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Short-chain fatty acids (SCFAs) are among the main classes of bacterial metabolic
products and are mainly synthesized in the colon through bacterial fermentation.
Short-chain fatty acids, such as acetate, butyrate, and propionate, reduce endothelial
activation induced by proinflammatory mediators, at least in part, by activation of G
protein–coupled receptors (GPRs): GPR41 and GPR43. The objective of the study
was to analyze the possible protective effects of SCFAs on endothelial dysfunction
induced by angiotensin II (AngII). Rat aortic endothelial cells (RAECs) and rat aortas
were incubated with AngII (1 µM) for 6 h in the presence or absence of SCFAs (5–
10 mM). In RAECs, we found that AngII reduces the production of nitric oxide (NO)
stimulated by calcium ionophore A23187; increases the production of reactive oxygen
species (ROS), both from the nicotinamide adenine dinucleotide phosphate oxidase
system and the mitochondria; diminishes vasodilator-stimulated phosphoprotein (VASP)
phosphorylation at Ser239; reduces GPR41 and GPR43 mRNA level; and reduces the
endothelium-dependent relaxant response to acetylcholine in aorta. Coincubation with
butyrate and acetate, but not with propionate, increases both NO production and
pSer239-VASP, reduces the concentration of intracellular ROS, and improves relaxation
to acetylcholine. The beneficial effects of butyrate were inhibited by the GPR41 receptor
antagonist, β-hydroxybutyrate, and by the GPR43 receptor antagonist, GLPG0794.
Butyrate inhibited the down-regulation of GPR41 and GPR43 induced by AngII, being
without effect acetate and propionate. Neither β-hydroxybutyrate nor GLPG0794 affects
the protective effect of acetate in endothelial dysfunction. In conclusion, acetate
and butyrate improve endothelial dysfunction induced by AngII by increasing the
bioavailability of NO. The effect of butyrate seems to be related to GPR41/43 activation,
whereas acetate effects were independent of GPR41/43.
Keywords: endothelial dysfunction, short-chain fatty acids, nitric oxide, angiotensin II, oxidative stress
Abbreviations: A23187, calcium ionophore calimycin; ACh, acetylcholine; AngII, angiotensin II; ApoE−/−,
apolipoprotein E knockout; AU, arbitrary units; BP, blood pressure; CM-H2DCFDA, 5-(and-6) chloromethyl-2′-7′-
dichlorodihydrofluorescein diacetate; DAF-2, diaminofluorescein-2; DHE, dihydroethidium; GLPG, GLPG0974; GPR,
G-protein-coupled receptor; HDACs, histone deacetylases; L-NAME, NG-nitro-L-arginine methyl ester; NO, nitric oxide;
Phe, phenylephrine; RAECs, rat aortic endothelial cells; ROS, reactive oxygen species; SCFAs, short-chain fatty acids; SHB,
β-hydroxybutyrate; VASP, vasodilator-stimulated phosphoprotein.
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INTRODUCTION
Vascular endothelial cells are critically involved in cardiovascular
homeostasis by controlling thrombotic, inflammatory, and
atherogenic states within vascular wall (Thomas et al., 2008).
Endothelial dysfunction is typified by a diminution of availability
of nitric oxide (NO), accompanied by high levels of reactive
oxygen species (ROS), a stimulation in the secretion of
proinflammatory cytokines along with a rise in the expression of
adhesion molecules (Cai and Harrison, 2000; Hadi et al., 2005;
Touyz and Briones, 2011). Endothelial dysfunction, defined as
a loss of endothelium to induce vasodilatation, is an earliest
indicator of development of cardiovascular disease and appears
in the onset and during the progression of hypertension,
atherosclerosis, cardiac ischemia, or stroke (Versari et al., 2009;
Dharmashankar and Widlansky, 2010; Gkaliagkousi et al., 2015;
Vasquez et al., 2019).
Angiotensin II (AngII) is the major effector peptide of
renin–angiotensin system. This peptide is a strong stimulus
for nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase, the main source of ROS in the vascular wall, which
induces vascular oxidative stress and endothelial dysfunction
(Virdis et al., 2011). In addition, chronic exposure to AngII
induces hypertension and vascular remodeling associated to
an increased production of NADPH oxidase-derived ROS
(Cifuentes et al., 2000).
The gut microbiota is considered important for cardiovascular
health (Tang et al., 2019). An ever-growing body of evidence has
implicated intestine dysbiosis in the development of hypertension
(Yang et al., 2015; Adnan et al., 2017; Li et al., 2017; Toral
et al., 2019a,b). Bacterial metabolites mediate interactions with
the host. Through resorption and distribution, they can affect
intestinal health, and distant immune system functions, the
vasculature, and the heart, as well (Bartolomaeus et al., 2019).
Short-chain fatty acids (SCFAs) are one of the principal classes
of bacterial metabolites. Under physiological conditions, SCFA
levels in peripheral blood are very low (in the µM to low mM
range) due to hepatic metabolism, with acetate being the main
SCFA in circulation (Peters et al., 1992). Nevertheless, high-
fiber-diet consumption increased total SCFA levels in serum,
with acetate being the most abundant (300 µM) (Thorburn
et al., 2015). Moreover, administration of the prodrug of butyrate
(Edelman et al., 2003), or intraperitoneal injection of propionate
(1 g/kg) (Kimura et al., 2011), or SCFA intravenously (McAndrew
et al., 1999), or parenteral nutrition supplemented with 9 mM
butyrate (Jirsova et al., 2019) raises SCFA concentrations
to high µM or mM levels in blood, which could present
a clinical application. Interestingly, chronic AngII infusion
to rat induced hypertension accompanied by a decrease in
acetate- and butyrate-producing bacteria (Yang et al., 2015),
and plasma butyrate was relatively depleted in hypertensive
patients (Kim et al., 2018). Butyrate, acetate, and propionate
have properties of an antihypertensive character (Natarajan and
Pluznick, 2014; Pluznick, 2014; Natarajan et al., 2016). These
metabolic products modulate blood pressure (BP) via the vascular
and renal G-protein–coupled receptor 41 (GPR-41), and GPR-
43 (which lower BP upon stimulation) and olfactory receptor
59 (capable of elevating BP) (Pluznick, 2013). For instance,
chronic butyrate treatment improved acetylcholine-induced
vasorelaxation and attenuated hypertension induced by AngII
infusion in mice (Kim et al., 2018). Acetate supplementation
was able to prevent the development of hypertension and
heart failure in a deoxycorticosterone acetate–salt murine
model of hypertension (Marques et al., 2017). The SCFA
propionate protects from AngII-induced cardiac and vascular
damage in AngII-infused apolipoprotein E knockout (ApoE−/−)
mice (Bartolomaeus et al., 2019). On the other hand, oral
supplementation with butyrate is able to decrease oxidative
stress in atherosclerotic lesion sites, attenuating endothelial
dysfunction and macrophage migration and activation in
ApoE−/− mice (Aguilar et al., 2016). Furthermore, SCFAs play
a beneficial role reducing endothelial activation, which leads
to a reduction in cytokine production and adhesion molecules
expression (Li et al., 2018a,b). Short-chain fatty acids might
modulate endothelial function either by activating GPRs (Vinolo
et al., 2011) and/or inhibiting histone deacetylases (HDACs).
However, whether the protective effects in vascular oxidative
stress and endothelial dysfunction induced by chronic SCFAs
in AngII-infused animals are related to direct effects in the
endothelium is unknown. Thus, the objective of the present
study was to examine the direct effects of SCFAs against
endothelial dysfunction induced by AngII in both rat aortic
endothelial cells (RAECs) and intact rat thoracic aorta and the
role of GPR41/43.
MATERIALS AND METHODS
Vascular Reactivity Studies
Descending thoracic aortic segments from rats were
maintained for 24 h in Medium 199 (Gibco, Invitrogen
Life Technologies, Carlsbad, CA, United States) + 20% fetal
bovine serum+ amphotericin B 2 mM+ penicillin/streptomycin
2 mM + glutamine 2 mM + HEPES 10 mM, all from Sigma-
Aldrich, Barcelona, Spain) at 37◦C under 5% CO2 (Robles-Vera
et al., 2018). During this time, the rings were incubated with
acetate (10 mM), propionate (10 mM), or butyrate (5 mM),
and in the last 6 h in AngII-free condition (control rings)
or under AngII (1 µM)–stimulated condition serum-free
Medium 199. In some experiments, rings were coincubated
for 24 h with the antagonist of GPR-43 receptor, GLPG0974
(GLPG) (Namour et al., 2016) (Bio-Techne R&D Systems,
S.LU, Madrid, Spain) (0.1 µM), or with β-hydroxybutyrate
(SHB), a ketone body and antagonist of GPR-41 (5 mM)
(Kimura et al., 2011) (Sigma-Aldrich). After the incubation
period, rings were mounted in organ chambers filled with
Krebs solution (2 mM CaCl2, 1.2 mM KH2PO4, 118 mM
NaCl, 25 mM NaHCO3, 4.75 mM KCl, 1.2 mM MgSO4 and
11 mM glucose) at 37◦C and gassed with 95% O2 and 5%
CO2 (Sanchez et al., 2007). The concentration–relaxation
response curves to acetylcholine (ACh, 1 nM to 10 µM) were
performed in rings precontracted by 1 µM phenylephrine (Phe).
Relaxant responses to ACh were expressed as a percentage of the
response to Phe.
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Primary Culture of Rat Aortic Endothelial
Cells
Rat aortic endothelial cells were obtained from rat thoracic
aortas as previously reported (Toral et al., 2015) with some
modifications. The resulting cells were cultured [Medium 199
(Gibco, Invitrogen Life Technologies) + 20% fetal bovine
serum + amphotericin B 2 mM + penicillin/streptomycin
2 mM + glutamine 2 mM + HEPES 10 mM + heparin
100 mg/mL + endothelial cell growth supplement 30 µg/mL; all
from Sigma-Aldrich] at 37◦C and 5% CO2. Rat aortic endothelial
cells were incubated with acetate (10 µM to 10 mM), propionate
(10 mM), or butyrate (1 µM to 5 mM), in serum free Medium
199 for 24 h. For the last 6 h in the appropriated wells, AngII
(1 µM) was added to induce a stimulated condition. In some
experiments, cells were coincubated for 24 h with the GPR-43
antagonist GLPG (0.1 µM), or with the GPR-41 antagonist, SHB
(5 mM). After the incubations, RAECs were used to analyze
NO, ROS production, mitochondrial ROS production, NADPH
oxidase activity, and gene and protein expression levels.
Quantification of NO Released by
Diaminofluorescein 2
A NO-sensitive fluorescent probe, diaminofluorescein 2 (DAF-
2) (Sigma-Aldrich), was employed for the quantification of NO
released by RAECs as previously described (Toral et al., 2015).
Succinctly, RAECs were incubated in 96-well plates, as already
mentioned. Then, cells were washed with phosphate-buffered
saline (PBS) + 0.9 mM Ca2+ and then were preincubated with
L-arginine (100 µM in PBS, 5 min, 37◦C) (Sigma-Aldrich).
Afterward, DAF-2 (0.1 µM) was added for 2 min, and then a
calcium ionophore, calimycin (A23187, 1 µM) (Sigma-Aldrich),
was incubated for 30 min. Subsequently, fluorescence intensity
[expressed as arbitrary units (AU)] was determined at excitation
and emission wavelengths of 490 and 510 nm, respectively,
using a spectrofluorometer (Fluorostart; BMG Labtechnologies,
Offenburg, Germany). Autofluorescence was subtracted from
all values. To determine NO-independent fluorescence signal
induced by A23187, NG-nitro-L-arginine methyl ester (L-NAME,
100 µM) was added to some wells 15 min before the addition of
L-arginine. The difference between the fluorescence signal with
and without L-NAME was considered as NO production.
Immunofluorescence in Cultured Cells
Rat aortic endothelial cells were then plated on gelatin-
coated plates and were incubated under the already mentioned
conditions. Cells were stimulated by the calcium ionophore
calimycin (A23187, 1 µM) for 30 min. Then, cells were fixed
in 4% formaldehyde in PBS for 10 min and permeabilized
with 0.5% Triton X-100 in PBS for 15 min. Cells were then
stained with antibody to mouse monoclonal anti–p-VASP-Ser239;
1:50; Santa Cruz Biotechnology, Santa Cruz, CA, United States).
Specificity was determined by substituting primary antibody with
unrelated immunoglobulin G (Santa Cruz Biotechnology). The
secondary antibody was Alexa-Fluor-546–conjugated goat anti–
mouse (BD Pharmingen, Franklin Lakes, NJ, United States).
Sections were mounted with DAPI in Citifluor AF4 mounting
medium (Aname, Madrid, Spain), as previously described (Du
et al., 2012). Images were acquired at 1,024 × 1,024 pixels, 8
bits, using a Leica SP5 (Madrid, Spain) confocal microscope with
40 × oil-immersion objective. The laser intensity and exposure
time were kept identical for all measurements.
Measurement of Intracellular ROS
Concentrations
The fluorescent probe 5-(and-6-)chloromethyl-2′-7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA)
(Invitrogen Life Technologies) was used to measure endothelial
ROS production. Confluent RAECs in 96-well plates were
incubated as described before. To assess the role of NADPH
oxidase in ROS production, some cells were also coincubated
with the selective NADPH oxidase inhibitor VAS2870 (10 µM)
(Sigma-Aldrich). During this period, the cells were incubated
with 5 µM CM-H2DCFDA for 30 min at 37◦C. After the
incubation, the cells were washed twice with PBS + 0.9 mM
Ca2+. Fluorescence levels were determined at excitation and
emission wavelengths of 490 and 545 nm, respectively, with
a spectrofluorometer (Fluorostart; BMG Labtechnologies)
(Toral et al., 2015).
Mitochondrial ROS Measurement
Mitochondrial ROS production was determined through
an already described method adequately modified for these
specifications (Wojtala et al., 2014), using the MitoSOXTM Red
(Invitrogen Life Technologies), a mitochondrial O2− molecular
sensor. Confluent RAECs were incubated as reported before.
Afterward, MitoSOXTM Red (5 µM) was added; some cells were
also coincubated with MitoQ (0.1 µM) (donated by Dr. M.
P. Murphy, Medical Research Council Mitochondrial Biology
Unit, Cambridge, United Kingdom) (selective scavenger of
mitochondrial ROS), and cells were incubated in the dark,
30 min at 37◦C. After, the media was removed, and the washing
of the cells with PBS + 0.9 mM Ca2+, fluorescent intensity
(expressed as relative fluorescent units), was determined through
excitation and emission wavelengths of 490 and 590 nm,
respectively, employing a spectrofluorometer (Fluorostart;
BMG Labtechnologies).
NADPH Oxidase Activity
The NADPH oxidase activity in intact RAECs was also
determined, as previously described, by dihydroethidium (DHE)
fluorescence assay in the microplate reader (Toral et al.,
2015). Confluent RAECs grown in 6-well dishes (well area of
9.6 cm2) incubated as previously described were washed with
cold PBS; harvested; homogenized using lysis buffer composed
of 50 mM Tris, pH 7.4, containing 0.1 mM EDTA, 0.1 mM
EGTA, 10 µg/mL aprotinin, 10 µg/mL leupeptin, and 1 mM
phenylmethysulfonyl fluoride; and sonicated (10 s of 3 cycles
al 8W). Ten micrograms of protein obtained from fresh
homogenates was incubated with DHE (10 µM) and DNA
(1.25 µg/mL) in phosphate buffer (100 mM), pH 7.4, containing
100 µM diethylenetriamine pentaacetic acid (PBS/DTPA) with
the addition of NADPH (50 µM), at a final volume of 120 µL.
Incubations were performed for 30 min at 37◦C, in the presence
or absence of VAS2870 (10 µM), in the absence of light.
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Total fluorescence was measured in a microplate reader using a
rhodamine filter (excitation 490 nm and emission 590 nm) with a
spectrofluorometer (Fluorostart; BMG Labtechnologies).
Reverse Transcriptase–Polymerase
Chain Reaction and Western Blot
Analysis
Reverse transcriptase–polymerase chain reaction (RT-PCR)
analysis was performed using standard methods; total RNA was
extracted from RAECs by homogenization and converted to
cDNA. Cells were scratched and harvested in 0.5 mL of Tri
Reagent (Thermo Fisher Scientific, Waltham, MA, United States).
RNA isolation was performed through conventional methods
consisting of sequential washes using bromochloropropane,
isopropanol, and ethanol 75%. RNA concentrations were
determined with a NanoDrop 2000 Spectrophotometer (Thermo
Fisher Scientific). Polymerase chain reaction was carried out
with a Techne Techgene thermocycler (Techne, Cambridge,
United Kingdom). Quantitative real-time RT-PCR was applied
to analyze mRNA expression. The utilized forward and reverse
primer sequences are included in Table 1. Previous experiments
were conducted with different amounts of cDNA in order to
find non-saturating conditions of PCR amplification for all genes
studied. The relative quantification of mRNA was judged by
the SYBR Green–based RT-PCR method. The quality of the
PCR reaction was determined according with dilution series
of a standard cells sample. The 11Ct method was used for
quantification. For internal normalization, the housekeeping
gene GAPDH was selected.
Western blotting was performed as described previously
(Toral et al., 2015). Rat aortic endothelial cell homogenates
were run on using sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Proteins were transferred to polyvinylidene
difluoride membranes and incubated with primary antibody
to mouse monoclonal anti-p-VASP-Ser239, rabbit monoclonal
anti-peNOS-ser-1177 antibody (Cell Signaling Technology,
Danvers, MA, United States), or mouse monoclonal anti-
eNOS (Endothelial nitric oxide synthase) antibody (Transduction
Laboratories, San Diego, CA, United States), and mouse
monoclonal anti–α-actin (Sigma-Aldrich) antibodies overnight
and with the corresponding secondary peroxidase-conjugated
antibodies. Antibody binding was detected by an ECL system
(Amersham Pharmacia Biotech, Amersham, United Kingdom),
and densitometric analysis was performed using Scion Image-
Release Beta 4.02 software1.
Statistical Analysis
All data are presented as mean ± SEM. Statistical analyses were
carried out with the GraphPad Prism 7 software (GraphPad
Software, San Diego, CA, United States). The Shapiro–Wilk test
was performed for normally distributed continuous variables.
Statistical comparisons were done using the one-way analysis
of variance with Dunnett procedure for post hoc analysis
1http://www.scioncorp.com
for parametric analysis or the Kruskal–Wallis test for non-
parametric analysis. Significance was considered for values
of p< 0.05.
RESULTS
Butyrate and Acetate Improve
AngII-Induced Impairment of
Endothelium-Dependent Vasodilation
and NO Production
Incubation of rat aortas with AngII inhibited the endothelium-
dependent relaxation to ACh (Figure 1A). In RAECs, AngII
reduced the A23187-stimulated NO production (Figure 1B) and
VASP phosphorylation at Ser239 (Figure 2). Supraphysiological
concentrations of butyrate and acetate treatment, but not
propionate, improved the aortic relaxation to ACh (Figure 1A),
A23187-stimulated NO generation (Figure 1B), and VASP-Ser239
phosphorylation (Figure 2) in aorta and RAECs exposed to
AngII, respectively. We also analyzed the effects of physiological
plasma concentrations of butyrate and acetate in NO generation
impaired by AngII in RAECs. We found that concentrations of
butyrate ≥100 µM and acetate ≥1 mM were able to prevent the
reduction in NO production induced by AngII (Supplementary
Figure S1). The protective effects of butyrate (5 mM) on
VASP-Ser239 phosphorylation in RAECs were also confirmed
by Western blot (Supplementary Figure S2A). Because GPR-
41 and GPR-43 are the two targets of SCFAs (Ang and Ding,
2016), we found that the effect of butyrate was inhibited by
coincubation with the antagonist of GPR-41, SHB, and by the
antagonist of GPR-43, GLPG (Figures 1, 2). Nonetheless, the
effect of acetate on endothelial dysfunction and NO release by
endothelial cells was not abrogated by any of the antagonists
(Figures 1, 2). When we analyzed eNOS phosphorylation at
the active site Ser1177, we found that AngII was unable to
reduce significantly the ratio peNOSSer1177/eNOS as compared
the control, and the presence of butyrate did not modify the
level of phosphorylation (Supplementary Figure S2B). In order
to examine whether NADPH oxidase–driven ROS production
is involved in endothelial dysfunction induced by AngII, we
measured the relaxation to ACh in aorta (Supplementary
Figure S3) and the phosphorylation of VASP at Ser239 by
immunofluorescence in RAECs incubated with the specific pan-
NOX inhibitor VAS2870. We found that both the impaired
ACh relaxation (Supplementary Figure S2) and the reduction
in VASP phosphorylation induced by AngII were prevented by
NADPH oxidase inhibition (Figure 2).
Butyrate, Acetate, and Propionate
Reduce the ROS Production Induced by
AngII
Because ROS is closely linked to endothelial dysfunction, we
analyzed the intracellular oxidative stress. It was measured
using the CM-H2DCFDA fluorescent probe. Compared with
control cells, the fluorescence signal in AngII-exposed cells
(Figure 3) was significantly ≈1.6-fold higher (181.8 ± 26.2
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TABLE 1 | Oligonucleotides for real-time RT-PCR.
mRNA targets Descriptions Sense Antisense
NOX-1 NOX-1 subunit of NADPH oxidase TCTTGCTGGTTGACACTTGC TATGGGAGTGGGAATCTTGG
p47phox p47phox subunit of NADPH oxidase CCCAGCGACAGATTAGAAGC TGGATTGTCCTTTGAGTCAGG
GPR-41 G-protein-coupled receptor-41 TGACGGTGAGCATAGAACGTTT GCCGGGTTTTGTACCACAGT
GPR-43 G-protein-coupled receptor-43 TCGTGGAAGCTGCATCCA GCGCGCACACGATCTTT
GAPDH Glyceraldehyde-3-phosphate dehydrogenase ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA
FIGURE 1 | Effects of short-chain fatty acids (SFCAs) in angiotensin (Ang) II–induced endothelial dysfunction in vitro. Vascular relaxant responses induced by
acetylcholine (ACh) (A) in rat aortas precontracted by phenylephrine (Phe, 1 µM) incubated with butyrate (5 mM), acetate (10 mM), or propionate (10 mM). In some
experiments, aortic rings were coincubated with GLPG0974 (GLPG, 0.1 µM) or β-hydroxybutyrate (SHB, 5 mM) for 24 h, and in the last 6 h in the absence (Ctrl) or
presence of AngII (1 µM). Results are shown as mean ± SEM, derived from six to eight different rings. *P < 0.05 and **P < 0.01 vs. ctrl; #P < 0.05 and ##P < 0.01
vs. AngII; +P < 0.05 vs. AngII + SFCA group. Nitric oxide (NO) release stimulated by A23187 (B) in RAECs incubated with butyrate (5 mM), acetate (10 mM), or
propionate (10 mM). In some experiments, cells were coincubated with GLPG0974 (GLPG, 0.1 µM) or SHB (5 mM) for 24 h, and in the last 6 h in the absence
(control) or presence of angiotensin (Ang)II (1 µM). Nitric oxide release was estimated from the area under the curve (AUC) of the fluorescent signal of
4,5-diaminofluorescein (DAF-2) for 30 min of stimulation. Results are shown as mean ± SEM (six to eight). **P < 0.01 vs. ctrl; #P < 0.05 and ##P < 0.01 vs. AngII;
+P < 0.05 vs. AngII + SFCA group.
vs. 299.8 ± 41.4 AU, P < 0.05, respectively). This ROS
increase was reduced by butyrate (159.0 ± 24.9 AU, P < 0.01),
acetate (38.9 ± 22.0 AU, P < 0.01) but not by propionate
(326.1 ± 30.0 AU, P > 0.05) (Figure 3). The effect of butyrate
was inhibited by coincubation with the antagonist of GPR-41,
SHB by ≈100%, and by the antagonist of GPR-43, GLPG
by ≈93% (Figure 3). However, the incubation with SHB or
GLPG did not change the effects of acetate (19.8 ± 15.2 and
37.9 ± 25.5 AU, respectively, P > 0.05 vs. acetate alone) or
propionate (311.6 ± 18.8 and 295.8 ± 31.1 AU, respectively,
P > 0.05 vs. propionate alone) (Figure 3). This ROS increase was
inhibited by the VAS2870, showing the critical role of increased
NADPH oxidase in the intracellular ROS production stimulated
by AngII (Figure 3). Additionally, the NADPH oxidase activity
was also increased by AngII, whereas butyrate (Figure 4A) and
acetate (Figure 4B) inhibited significantly this increase, with
propionate being without effect (Figure 4C). Again both SHB and
GLPG inhibited the effects of butyrate, with acetate being without
effects (Figure 3). Similarly, butyrate abolished the up-regulation
of NOX-1 and p47phox mRNA in RAECs incubated with AngII.
Once more, this effect was reversed when combined with SHB
or GLPG (Figure 4A). However, the acetate treatment prevented
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FIGURE 2 | Effects of short-chain fatty acids (SFCAs) in VASP phosphorylation in rat aortic endothelial cells (RAECs). Pictures show VASP (Ser239) phosphorylation
in RAECs incubated with butyrate (5 mM), acetate (10 mM), or propionate (10 mM). In some experiments, cells were coincubated with GLPG0974 (GLPG, 0.1 µM)
or β-hydroxybutyrate (SHB, 5 mM) for 24 h, and in the last 6 h in the absence (Ctrl) or presence of angiotensin (Ang)II (1 µM), measured by immunostaining (red
fluorescence) intensity normalized to the blue nuclear stain DAPI. Cells were stimulated by the calcium ionophore calimycin (A23187, 1 µM) for 30 min. Scale bar,
50 µm. Results are shown as mean ± SEM (four to six). *P < 0.05 vs. ctrl; #P < 0.05 vs. AngII; +P < 0.05 vs. AngII + SFCA group.
FIGURE 3 | Effects of short-chain fatty acids (SFCAs) in intracellular reactive oxygen species (ROS) production in rat aortic endothelial cells (RAECs). Reactive
oxygen species were measured by fluorescence in CM-H2DCFDA-loaded cells in RAECs incubated with butyrate (5 mM), acetate (10 mM), or propionate (10 mM). In
some experiments, cells were co-incubated with GLPG0974 (GLPG, 0.1 µM) or β-hydroxybutyrate (SHB, 5 mM) for 24 h, and in the last 6 h in the absence (control)
or presence of AngII (100 µM). Results are shown as mean ± SEM (six to eight). **P < 0.01 vs. ctrl; ##P < 0.01 vs. AngII; ++P < 0.01 vs. AngII + SFCA group.
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FIGURE 4 | Effects of short-chain fatty acids (SFCAs) in NADPH oxidase in rat aortic endothelial cells (RAECs). NADPH oxidase activity measured by DHE
fluorescence and mRNA levels of NADPH oxidase subunits NOX-1 and p47phox in RAECs incubated with butyrate (5 mM, A), acetate (10 mM, B), or propionate
(10 mM, C). In some experiments, cells were coincubated with GLPG0974 (GLPG, 0.1 µM) or β-hydroxybutyrate (SHB, 5 mM) for 24 h, and in the last 6 h in the
absence (control) or presence of AngII (1 µM). Results are shown as mean ± SEM (six to eight). **P < 0.01 vs. ctrl; #P < 0.05 and ##P < 0.01 vs. AngII; +P < 0.05
and ++P < 0.01 vs. AngII + SFCA group.
the up-regulation of NOX-1 and p47phox in AngII-treated cells.
This effect was not altered by GLPG or SHB (Figure 4B). By
contrast, propionate did not affect the significant mRNA increase
of the main NADPH oxidase subunits in RAECs incubated with
AngII (Figure 4C).
Butyrate and Acetate Reduce the
Mitochondrial ROS Production Induced
by AngII
Mitochondria are large generators of ROS during the process
of oxidative phosphorylation. These ROS are able to bind to
NO and reduce its bioavailability. It led us to analyze the action
of SCFAs on the mitochondrial ROS production. Mitochondrial
ROS were measured by MitoSOXTM Red in RAECs. Its signal
was increased after incubation with AngII. This ROS increase
was reduced by butyrate and acetate but not by propionate
(Figure 5A). To confirm the role of mitochondrial ROS, cells
were incubated with the mitochondrial antioxidant mitoQ, which
lowered the high ROS production induced by AngII (Figure 5A).
The effect of butyrate was abolished by coincubation with
the antagonists SHB and GLPG (Figure 5B). However, the
effect of acetate was not modulated by any of the antagonists
used (Figure 5B).
Butyrate Prevents GPR-41 and GRP-43
Down-Regulation Induced by AngII in
RAECs
To examine if shifts in GPRs expression levels were involved
in the protective effects of SCFAs in endothelial function, the
mRNA levels of GPR-41 and GPR-43 were measured in RAECs.
Angiotensin II induced a significant down-regulation of both
GPRs (Figure 6). Coincubation with butyrate but not with
acetate or propionate increased mRNA levels of both GPR-41
and GPR-43.
DISCUSSION
Our research demonstrates, for the first time, that butyrate
and acetate, at concentrations raised under pharmacological
interventions, improve endothelial dysfunction induced by the
prohypertensive agent AngII by increasing the bioavailability
of NO involving GPR activation. The principal findings of
the present study are the following: (1) butyrate and acetate
restored endothelium-dependent vasodilatation in aortic rings
and increased calcium ionophore–stimulated NO production
by endothelial cells incubated with AngII; (2) both SCFAs
decreased intracellular ROS production from NADPH oxidase
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FIGURE 5 | Effects of short-chain fatty acids (SFCAs) in mitochondrial ROS in rat aortic endothelial cells (RAECs). Mitochondrial ROS (A) in the presence of the
antioxidant mitoQ (0.1 µM) during AngII incubation in RAECs incubated with butyrate (5 mM), acetate (10 mM), or propionate (10 mM). In some experiments (B),
cells were coincubated with GLPG0974 (GLPG, 0.1 µM) or β-hydroxybutyrate (SHB, 5 mM) for 24 h, and in the last 6 h in the absence (control) or presence of AngII
(1 µM). Results are shown as mean ± SEM (six to eight). *P < 0.05 vs. ctrl; #P < 0.05 vs. AngII; +P < 0.05 vs. AngII + SFCA group.
and mitochondria; (3) these SCFAs restored the phosphorylation
of VASP at Ser239; and (4) GPR-41 and GPR-43 antagonists
inhibit the beneficial effects of butyrate in AngII-induced
endothelial dysfunction, without affecting acetate effects.
Endothelial dysfunction presents a characteristic shift of
activity from the endothelium toward reduced vasodilation.
Nitric oxide is the main endothelium-dependent vasodilator in
the aorta. In fact, the incubation with the eNOS blocker L-NAME
abolished ACh-induced relaxation in rat aorta (Gómez-Guzmán
et al., 2015). Nitric oxide–induced relaxation is linked to high
levels of cGMP in vascular smooth muscle cells, an interaction
known as the NO-cGMP signaling pathway. Disturbance of
NO signaling pathways is one of the major determinants for
endothelial dysfunction, which is characterized by the reduction
of the NO bioavailability with the resulting impairment of the
endothelium-dependent vasodilation (Endemann and Schiffrin,
2004). In all cases, p-VASP-Ser239 can be used as a sensitive
marker of the NO-cGMP pathway (Wang et al., 2019). Recently,
it has been shown that, in vascular tissue where endothelial
dysfunction is present and NO bioavailability is decreased,
VASP phosphorylation at Ser239 was strikingly reduced (Oelze
et al., 2000; Mülsch et al., 2001). Mollnau et al. (2002)
found that AngII infusion caused endothelial dysfunction in
vessels linked to a strong decrease in p-VASP-Ser239. It is
unlikely that the observed reduction in p-VASP-Ser239 was
caused by a depletion in substrate availability, because total
VASP expression was patently similar in vessels from sham-
treated and AngII-infused animals. In agreement with this
information, our data showed that p-VASP-Ser239 was reduced
in AngII-treated endothelial cells. This suggests the involvement
of an impaired NO-cGMP pathway in endothelial-dependent
smooth muscle relaxation reduction in aortic rings incubated
with AngII. Interestingly, butyrate and acetate improved the
impaired NO-cGMP pathway. This protective effect of both
SCFAs was supported by (i) increased NO production and
VASP phosphorylation at Ser239 in RAECs and (ii) increased
endothelium-dependent vasorelaxation to ACh in aortic rings
incubated with AngII. The protective effects of butyrate seem to
be independent of increased eNOS activation, because butyrate
did not change eNOS phosphorylation at the active site Ser1177.
However, we did not find beneficial effects of propionate on
endothelial dysfunction induced by AngII. This result suggests
that the improvement in vascular dysfunction and hypertension
in AngII–infused wild-type NMRI mice and AngII-infused
ApoE−/− mice induced by propionate (Bartolomaeus et al.,
2019) seems to be independent of direct effects in the NO-GMPc
pathway in the vascular wall.
An excessive production of ROS is crucially associated
with the breakdown of NO linked to endothelial dysfunction
in vascular tissues from AngII-infused rats (Rajagopalan
et al., 1996; Virdis et al., 2004). It is well established that
endothelial dysfunction induced by AngII was also associated
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FIGURE 6 | Effects of short-chain fatty acids (SFCAs) in GRPs expression in
rat aortic endothelial cells (RAECs). mRNA levels of GRP41 and GRP43 in
RAECs incubated with butyrate (5 mM), acetate (10 mM), or propionate
(10 mM) for 24 h, and in the last 6 h in the absence (control) or presence of
AngII (1 µM). Results are shown as mean ± SEM (six to eight). **P < 0.01 vs.
control; ##P < 0.01 vs. AngII.
with increased production of ROS from both NADPH oxidase
(Griendling et al., 1994; Li and Shah, 2003; Sanchez et al.,
2007) and mitochondria (Doughan et al., 2008; Dikalov
et al., 2014) in vascular cells. In our experiments, the
mitochondrial antioxidant mitoQ and the NADPH oxidase
inhibitor VAS2870 prevented the AngII-induced increase in
mitochondrial and intracellular ROS, respectively. Interestingly,
VAS2870 restored ACh-induced relaxation and p-VASP- Ser239
level in AngII-treated aorta and RAECs, respectively, confirming
the critical involvement of NADPH oxidase in AngII-induced
endothelial dysfunction. The elevated NADPH oxidase activity
induced by AngII was associated with increased expression
of its subunits NOX-1 and p47phox. Butyrate and acetate
prevented the increased ROS levels. This effect was caused
by reducing both mitochondrial and NADPH oxidase-derived
ROS production in endothelial cells. The normalization of
ROS also seems to contribute to the restoration of endothelial
function. Our results suggest that the decrease in ROS
levels in the vascular wall and the ensuing prevention of
NO inactivation constitute a pivotal mechanism involved
in the SCFAs’ protective effects on endothelial function.
The present results agree with previous data showing that
attenuation of endothelium dysfunction, macrophage migration,
and activation in the atherosclerotic lesion in ApoE−/− mice
induced butyrate supplementation linked to a decrease in
oxidative stress related to a reduced NADPH oxidase expression
(Aguilar et al., 2016).
Short-chain fatty acids might modulate endothelial function
either through the inhibition of HDACs and/or the activation
of GPRs: GPR-41 and GPR-43 (Vinolo et al., 2011). Activation
of GPR41/43 mediated, at least in part, the inhibitory effects
of SCFAs in cytokine production stimulated by LPS or TNFα
in human umbilical vein endothelial cells (Li et al., 2018b).
Our studies found a crucial role of GPR-41 and GPR-43 in
the protective effects of butyrate on endothelial dysfunction
and oxidative stress induced by AngII. Our results demonstrate
that pharmacological blockade of GPR-41 by SHB, and GPR-
43 by GLPG, inhibited the protective effects of butyrate
on NO production, intracellular ROS accumulation, VASP
FIGURE 7 | Scheme representing the mechanisms for the protective effect of
short-chain fatty acids (SFCAs) (in red) involved in the angiotensin
(Ang)II–induced impairment of endothelial function).
phosphorylation, and endothelium-dependent relaxation to ACh.
Nevertheless, we also found that acetate prevented endothelial
dysfunction induced by AngII in a GPR-independent manner,
because it was unaffected by its antagonists. A reduced GPR-
41 expression in aorta has been associated to reduced plasma
butyrate levels and high BP in spontaneously hypertensive rats,
as compared to Wistar–Kyoto rats (Robles-Vera et al., 2017;
Kim et al., 2018). Interestingly, we found that AngII down-
regulated both GPR41 and GPR43 in endothelial cells. This effect
was significantly inhibited by butyrate, whereas both acetate
and propionate were without effect. This enhanced expression
of GPR41/43 induced by butyrate in RAECs might account
for its protective effects in endothelial function. However, the
interaction between activated GPR41/43 and AngII pathways
to prevent endothelial dysfunction has not been addressed in
the present study.
CONCLUSION
In conclusion, butyrate and acetate improved endothelial
dysfunction induced by AngII by an increase in NO
bioavailability as a result of oxidative stress inhibition.
The effects of butyrate seem to be dependent of GPR41/43
activation, whereas the preventive effects of acetate were GPR-
independent (Figure 7). These actions in the endothelium might
be associated with the vascular protective effect of chronic SCFA
supplementation in hypertension and atherosclerosis induced
by AngII described previously. In addition, gut microbiota
modifications by prebiotics or probiotics addressed to increase
plasma acetate and/or butyrate levels might be beneficial to
prevent the detrimental effects of AngII in the vascular wall.
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